Related Experiment Video
Updated: Jul 14, 2026
11:30
Procedure for Decellularization of Porcine Heart by Retrograde Coronary Perfusion
Published on: December 6, 2012
Tissue engineering of heart valves using decellularized xenogeneic or polymeric starter matrices
Dörthe Schmidt1, Ulrich A Stock, Simon P Hoerstrup
1Department of Surgical Research and Clinic for Cardiovascular Surgery, University Hospital and University of Zürich, Raemistrasse 100, CH 8091 Zürich, Switzerland.
Summary
Tissue engineering aims to create living heart valves that can grow and repair, overcoming limitations of current replacements. This review explores decellularized xenogeneic and polymeric scaffolds for generating functional, regenerative heart valves.
Area of Science:
- Regenerative Medicine
- Biomaterials Science
- Cardiovascular Surgery
Background:
- Heart valve replacement is standard for end-stage valvular heart disease.
- Current artificial valves lack growth, repair, and remodeling capabilities.
- Tissue engineering offers a promising alternative for functional, living heart valve replacements.
Purpose of the Study:
- To provide a comprehensive overview of tissue-engineered heart valve concepts.
- To compare decellularized xenogeneic and polymeric scaffold approaches.
- To discuss limitations and future directions for clinical application.
Main Methods:
- Utilizes starter matrices (decellularized xenogeneic or polymeric materials) shaped as heart valves.
- Involves subsequent cell seeding onto these matrices.
- Reviews existing literature on scaffold types and tissue engineering strategies.
Main Results:
- Both decellularized xenogeneic and polymeric scaffolds are viable options for heart valve tissue engineering.
- The choice of scaffold impacts the development of functional, living heart valve replacements.
- Current limitations include scaffold integration, cell viability, and long-term function.
Conclusions:
- Tissue engineering holds significant potential for developing regenerative heart valves.
- Further research is needed to address current limitations before clinical translation.
- Future efforts should focus on optimizing scaffold design, cell sourcing, and in vivo performance.
